Superworth

Amneal Pharmaceuticals PE ratio AMRX

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026
41.6×
6-year median
51.5×
Against its 6-year history
32nd
percentile: 0 is its lowest day, 100 its highest
6-year range
8.0× to 177×
Peer median
97.0×

Amneal Pharmaceuticals' PE ratio is 41.6× as of Oct 23, 2026: a share price of $20.38 against $0.49 of earnings per share over the last twelve months.

That is below its 6-year median of 51.5×, lower than on 68% of days in the last 6 years.

Over that time it ranged from 8.0× in Mar 2021 to 177× in Jul 2022.

The median for 10 large drugmakers of a similar size is 97.0×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far41.6×31.4×60.5×
2025n/m a value too high to mean anything
202489.8×89.8×99.8×
2023101×70.3×101×
2022159×48.4×177×
202153.2×8.0×94.5×
202011.1×9.9×11.1×

Against its peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.

CompanyPE ratio
AMRXAmneal Pharmaceuticals41.6×
LGNDLigand Pharmaceuticals32.3×
KNSAKiniksa Pharmaceuticals International79.1×
ALKSAlkermes plc.115×
TGTXTG Therapeutics19.8×
PTGXProtagonist Therapeutics134×
CORTCorcept Therapeutics204×
INDVIndivior Pharmaceuticals12.4×
ARQTArcutis Biotherapeutics142×
BMRNBiomarin Pharmaceutical151×
LQDALiquidia30.7×
Peer median97.0×

Where Amneal Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Amneal Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.